Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Relay Therapeutics and raises the price target from $14 to $17.
September 10, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Peter Lawson has maintained an Overweight rating on Relay Therapeutics and increased the price target from $14 to $17, indicating a positive outlook for the stock.
The increase in price target from $14 to $17 by Barclays suggests a positive outlook for Relay Therapeutics, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100